MCID: HRP006
MIFTS: 65

Herpes Simplex

Categories: Fetal diseases, Infectious diseases, Mental diseases, Oral diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Herpes Simplex

MalaCards integrated aliases for Herpes Simplex:

Name: Herpes Simplex 12 54 42 44 15
Herpesvirus Hominis Disease 12
Herpes Simplex Infections 71
Herpes Simplex Disease 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8566
ICD9CM 34 054
MeSH 44 D006561
NCIt 50 C155871
SNOMED-CT 67 88594005
ICD10 32 B00.9
UMLS 71 C0019348

Summaries for Herpes Simplex

MedlinePlus : 42 Herpes is an infection that is caused by a herpes simplex virus (HSV). Oral herpes causes cold sores around the mouth or face. Genital herpes affects the genitals, buttocks or anal area. Genital herpes is a sexually transmitted disease (STD). It affects the genitals, buttocks or anal area. Other herpes infections can affect the eyes, skin, or other parts of the body. The virus can be dangerous in newborn babies or in people with weak immune systems. There are two types of HSV: HSV type 1 most commonly causes cold sores. It can also cause genital herpes. HSV type 2 is the usual cause of genital herpes, but it also can infect the mouth. HSV spreads through direct contact. Some people have no symptoms. Others get sores near the area where the virus has entered the body. They turn into blisters, become itchy and painful, and then heal. Most people have outbreaks several times a year. Over time, you get them less often. Medicines to help your body fight the virus can help lessen symptoms and decrease outbreaks.

MalaCards based summary : Herpes Simplex, also known as herpesvirus hominis disease, is related to herpes simplex encephalitis and genital herpes, and has symptoms including fever, pruritus and snoring. An important gene associated with Herpes Simplex is NECTIN1 (Nectin Cell Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Acyclovir and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include mouth, face and genitalia, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A viral infectious disease that results in formation of lesions, located in mouth, located in face, located in genitalia, or located in hands, has material basis in Human herpesvirus 1 or has material basis in Human herpesvirus 2, which are transmitted by direct contact with an active lesion or body fluid of an infected person.

Wikipedia : 74 Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known by their taxonomical names Human... more...

Related Diseases for Herpes Simplex

Diseases in the Herpes Simplex family:

Congenital Herpes Simplex

Diseases related to Herpes Simplex via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1228)
# Related Disease Score Top Affiliating Genes
1 herpes simplex encephalitis 33.4 UNC93B1 TRAF3 TLR3 TICAM1 TBK1 IRF3
2 genital herpes 33.2 TNFRSF14 NECTIN1 IFI16
3 encephalitis 32.7 UNC93B1 TRAF3 TLR3 TICAM1 IRF3
4 herpetic whitlow 32.6 TNFRSF14 PILRA NECTIN1
5 acute retinal necrosis syndrome 32.3 TNFRSF14 NECTIN1
6 measles 31.4 TLR3 STAT1 IRF3 EIF2AK2
7 human immunodeficiency virus type 1 31.4 TLR3 STAT1 IRF3 CASP8
8 viral infectious disease 31.3 TLR3 TBK1 STAT1 IRF3 EIF2AK2
9 mumps 31.2 TLR3 STAT1 EIF2AK2
10 acute necrotizing encephalitis 31.1 UNC93B1 TLR3
11 hepatitis 31.1 TICAM1 TBK1 IRF3 EIF2AK2
12 newcastle disease 31.0 TLR3 IRF3 EIF2AK2
13 japanese encephalitis 31.0 TLR3 STAT1 IRF3
14 rabies 30.9 TLR3 STAT1 PML IRF3
15 hepatitis c 30.6 TLR3 STAT1 IRF3 EIF2AK2
16 influenza 30.5 TLR3 STAT1 PML IRF3 EIF2AK2
17 severe acute respiratory syndrome 30.5 TRAF3 TBK1 STAT1 IRF3
18 encephalopathy, acute, infection-induced 2 11.8
19 encephalopathy, acute, infection-induced 1 11.8
20 eczema herpeticum 11.7
21 congenital herpes simplex 11.7
22 herpes simplex virus keratitis 11.6
23 encephalopathy, acute, infection-induced 5 11.6
24 encephalopathy, acute, infection-induced 8 11.6
25 encephalopathy, acute, infection-induced 7 11.5
26 encephalopathy, acute, infection-induced 6 11.5
27 neonatal herpes 11.5
28 erythema multiforme 11.4
29 keratitis, hereditary 11.3
30 mollaret meningitis 11.3
31 torch syndrome 11.2
32 herpes simplex virus stromal keratitis 11.2
33 chickenpox 11.2
34 human cytomegalovirus infection 11.2
35 proctitis 11.2
36 aphthous stomatitis 11.1
37 viral pneumonia 11.1
38 cytomegalic inclusion disease 11.1
39 immunodeficiency 31a 11.1
40 herpetic gastritis 11.1
41 hyper-ige recurrent infection syndrome 2, autosomal recessive 11.1
42 hydrocephalus, endocardial fibroelastosis, and cataracts 11.1
43 caspase 8 deficiency 11.1
44 immunodeficiency 62 11.1
45 salivary gland disease 11.1
46 pseudomembranous conjunctivitis 11.1
47 congenital intrauterine infection-like syndrome 11.1
48 pudendal neuralgia 11.1
49 recessive dystrophic epidermolysis bullosa-generalized other 11.1
50 neurological consequences of cytomegalovirus infection 11.1

Graphical network of the top 20 diseases related to Herpes Simplex:



Diseases related to Herpes Simplex

Symptoms & Phenotypes for Herpes Simplex

UMLS symptoms related to Herpes Simplex:


fever, pruritus, snoring, halitosis, pelvic pain

GenomeRNAi Phenotypes related to Herpes Simplex according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.03 EIF2AK2 TBK1
2 Decreased viability GR00221-A-2 10.03 EIF2AK2 TBK1
3 Decreased viability GR00221-A-3 10.03 EIF2AK2
4 Decreased viability GR00221-A-4 10.03 EIF2AK2
5 Decreased viability GR00249-S 10.03 CREB3 TBK1 TICAM1 TLR3 TRAF3
6 Decreased viability GR00301-A 10.03 EIF2AK2 TBK1
7 Decreased viability GR00342-S-1 10.03 TBK1 TLR3
8 Decreased viability GR00342-S-2 10.03 TBK1 TLR3
9 Decreased viability GR00386-A-1 10.03 CREB3 TAP1 UNC93B1
10 Decreased viability GR00402-S-2 10.03 TBK1 TICAM1 TLR3 TNFRSF14
11 Increased the percentage of infected cells GR00402-S-1 8.32 TLR3

MGI Mouse Phenotypes related to Herpes Simplex:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 CASP8 EIF2AK2 IFI16 IRF3 PILRA PML
2 homeostasis/metabolism MP:0005376 10.2 CASP8 CREB3 IFI16 IRF3 NECTIN1 PILRA
3 immune system MP:0005387 10.13 CASP8 EIF2AK2 IFI16 IRF3 PILRA PML
4 mortality/aging MP:0010768 9.86 CASP8 CREB3 EIF2AK2 HCFC1 NECTIN1 PILRA
5 liver/biliary system MP:0005370 9.81 CASP8 HCFC1 PILRA POU2F1 STAT1 TBK1
6 neoplasm MP:0002006 9.17 CASP8 EIF2AK2 PML STAT1 TAP1 TICAM1

Drugs & Therapeutics for Herpes Simplex

Drugs for Herpes Simplex (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acyclovir Approved Phase 4 59277-89-3 2022
2
Metronidazole Approved Phase 4 443-48-1 4173
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Difluprednate Approved Phase 4 23674-86-4 443936
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Anti-Infective Agents Phase 4
12 Antiviral Agents Phase 4
13 valacyclovir Phase 4
14 Anti-Bacterial Agents Phase 4
15 Anti-HIV Agents Phase 4
16 Denatonium Phase 4
17 Antiparasitic Agents Phase 4
18 Antiprotozoal Agents Phase 4
19 Ophthalmic Solutions Phase 4
20 Methylprednisolone Acetate Phase 4
21
Methylene blue Approved, Investigational Phase 3 61-73-4
22
Famciclovir Approved, Investigational Phase 3 104227-87-4 3324
23
Aluminum sulfate Approved Phase 3 10043-01-3
24
Vidarabine Approved, Investigational Phase 3 24356-66-9 32326 21704
25
Zinc Approved, Investigational Phase 3 7440-66-6 32051
26
Halofantrine Approved Phase 3 69756-53-2 37393
27
Sodium citrate Approved, Investigational Phase 3 68-04-2
28
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
29
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
31 Gastrointestinal Agents Phase 3
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 glucocorticoids Phase 3
35 Antineoplastic Agents, Hormonal Phase 3
36 Antiemetics Phase 3
37 Neuroprotective Agents Phase 3
38 interferons Phase 3
39 Protective Agents Phase 3
40 Radiation-Protective Agents Phase 3
41 Vaccines Phase 3
42 Immunologic Factors Phase 3
43 Adjuvants, Immunologic Phase 3
44 Monophosphoryl lipid A Phase 3
45 polysaccharide-K Phase 3
46 Antimetabolites Phase 3
47 Anti-Retroviral Agents Phase 3
48 Anti-Inflammatory Agents Phase 3
49 5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
2 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00723229 Phase 4 acyclovir
3 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00362297 Phase 4 acyclovir;valacyclovir
4 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT01346475 Phase 4 valacyclovir;Valacyclovir
5 A Randomized, Double-Blind, Placebo Controlled Crossover Trial Using Valacyclovir to Suppress HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons Completed NCT00161434 Phase 4 valacyclovir;placebo
6 Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01448616 Phase 4 TDF;Placebo Vaginal Gel;Vaginal TFV Gel;Placebo Tablets
7 Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia Completed NCT01794897 Phase 4 Experimental: Valacyclovir treatment;Placebo comparator
8 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
9 A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons Completed NCT00527618 Phase 4 valacyclovir;acyclovir
10 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Orofacial Herpes Infections. Recruiting NCT04065971 Phase 4 2LHERP®;Placebo
11 A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis Recruiting NCT03626376 Phase 4 oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily;oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
12 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Genital Herpes Infections Not yet recruiting NCT04235322 Phase 4 2LHERP®;Placebo
13 Comparison Between the Sensibility of the Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis Terminated NCT02045082 Phase 4
14 Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System Unknown status NCT00006132 Phase 3 acyclovir
15 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects Unknown status NCT00005663 Phase 3 Valacyclovir hydrochloride
16 A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections Unknown status NCT03178747 Phase 3
17 Herpetic Eye Disease Study (HEDS) I Unknown status NCT00000138 Phase 3 Prednisolone Phosphate;Acyclovir
18 A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection Completed NCT00098059 Phase 3 Famciclovir
19 A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative Completed NCT00057330 Phase 3
20 Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine Completed NCT00000985 Phase 3 Vidarabine;Acyclovir;Foscarnet sodium
21 A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204) Completed NCT00031486 Phase 3 Valacyclovir;Placebo
22 Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth Completed NCT00006135 Phase 3 acyclovir
23 Study to Evaluate the Safety of GSK Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease Completed NCT00698568 Phase 3
24 A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis Completed NCT01321359 Phase 3 Vehicle versus NB-001
25 A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2-AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years. Completed NCT00224484 Phase 3
26 A Phase III, Double-blind, Randomized, Study to Compare: 1) the Immunogenicity and Safety of 3 Commercial Scale Consistency Lots of GlaxoSmithKline (GSK) Biologicals' Herpes Simplex Candidate Vaccine in Healthy HSV-1 and -2 Seronegative (HSV 1-/2-) Female Subjects Aged 10 - 17 Years, and 2) Vaccine Immunogenicity in Healthy HSV 1-/2- Females Aged 10 - 17 Years With Healthy HSV 1-/2- Adult Females Completed NCT00224471 Phase 3
27 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples Completed NCT00001649 Phase 3 Valaciclovir
28 Phase III Study of ASP2151 in Herpes Simplex Patients - A Double-blind, Placebo-controlled Study - Completed NCT01959295 Phase 3 ASP2151;ASP2151 placebo
29 Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth Completed NCT00004757 Phase 3 acyclovir
30 Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease Completed NCT00699764 Phase 3
31 A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving the Central Nervous System Completed NCT00031460 Phase 3 Acyclovir;Placebo
32 A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye, and Mouth Completed NCT00031447 Phase 3 Acyclovir;Placebo
33 A Randomized, Double-blind, Placebo-controlled, Multi-Center Trial of Zinc for the Treatment of Herpes Simplex Labialis (HSL) Completed NCT00809809 Phase 3 Zicam (Ionic zinc);placebo
34 A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients Completed NCT01602562 Phase 3 VACV tablets (Adults or pediatrics) or granules (pediatrics)
35 Open-label Study of ASP2151 in Herpes Simplex Patients Completed NCT02209324 Phase 3 ASP2151
36 Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient Completed NCT00855309 Phase 3 acyclovir sodium
37 A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection Completed NCT01386294 Phase 3 Tenofovir gel;Universal placebo gel
38 A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis Completed NCT00361881 Phase 3 ME-609;acyclovir in ME-609 vehicle;Vehicle
39 An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents Completed NCT00375570 Phase 3 ME-609
40 A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients Completed NCT00735761 Phase 3 ME-609;Acyclovir in ME-609 vehicle (5% acyclovir)
41 Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis Completed NCT02265913 Phase 3 Acyclovir 5 percent (Perrigo);Acyclovir 5 percent (Reference);Placebo cream
42 VALacyclovir for Inflammation AttenuatioN Trial Pilot (VALIANT Pilot) Completed NCT01176409 Phase 3 Valacyclovir;Placebo
43 A Randomized,Double-Blind , Placebo-Controlled Crossover Trial of Antivirals for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Co-infected Persons Completed NCT00465205 Phase 3 Valacyclovir;Matching Placebo
44 A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM). Completed NCT00378976 Phase 3 valacyclovir;matching placebo
45 Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples Completed NCT00194519 Phase 3 Generic acyclovir;Placebo
46 Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa Completed NCT00164424 Phase 2, Phase 3 Acyclovir
47 Herpetic Eye Disease Study (HEDS) II Completed NCT00000139 Phase 3 Acyclovir
48 VALacyclovir In Delaying Antiretroviral Treatment Entry Completed NCT00860977 Phase 3 valacyclovir;Placebo
49 Dexamethasone in Herpes Simplex Virus Encephalitis Open Label Randomized Controlled Trial With an Observer-blinded Evaluation at 6 Months Recruiting NCT03084783 Phase 3 Dexamethasone
50 A Prospective, Randomized Trial of Antiviral Prophylaxis in a Population of Burn Patients Withdrawn NCT02349828 Phase 2, Phase 3 Acyclovir

Search NIH Clinical Center for Herpes Simplex

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Acyclovir
Acyclovir Sodium
Benzocaine
BENZOCAINE PWDR
famciclovir
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Herpes Simplex Virus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Methylene blue
valacyclovir
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes simplex

Genetic Tests for Herpes Simplex

Anatomical Context for Herpes Simplex

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Simplex:

19
Mouth, Face, Genitalia, Hands

MalaCards organs/tissues related to Herpes Simplex:

40
Skin, T Cells, Eye, Prostate, Endothelial, Bone Marrow, Breast

Publications for Herpes Simplex

Articles related to Herpes Simplex:

(show top 50) (show all 30294)
# Title Authors PMID Year
1
Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis. 42 61
33265920 2020
2
Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules. 42
33105694 2020
3
In Reply. 42
32590707 2020
4
A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. 54 61
20375153 2010
5
Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. 61 54
20130048 2010
6
Glycoprotein D actively induces rapid internalization of two nectin-1 isoforms during herpes simplex virus entry. 61 54
20089288 2010
7
Role of the HCF-1 basic region in sustaining cell proliferation. 61 54
20126307 2010
8
Herpes simplex virus tegument ICP0 is capsid associated, and its E3 ubiquitin ligase domain is important for incorporation into virions. 61 54
19906912 2010
9
Efficient repair of DNA double-strand breaks in malignant cells with structural instability. 61 54
19909760 2010
10
T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. 54 61
19915044 2009
11
Fusion between perinuclear virions and the outer nuclear membrane requires the fusogenic activity of herpes simplex virus gB. 61 54
19759132 2009
12
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. 61 54
19521665 2009
13
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. 61 54
19702506 2009
14
[Expression of blood Toll-like receptors and cytokines in children with recurrent herpes simplex]. 61 54
19755019 2009
15
Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. 61 54
19386594 2009
16
Human mitochondrial thymidine kinase is selectively inhibited by 3'-thiourea derivatives of beta-thymidine: identification of residues crucial for both inhibition and catalytic activity. 61 54
19233899 2009
17
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. 54 61
19426226 2009
18
A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy. 61 54
19443362 2009
19
Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. 54 61
19279115 2009
20
Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone. 61 54
19429458 2009
21
Herpesvirus gB-induced fusion between the virion envelope and outer nuclear membrane during virus egress is regulated by the viral US3 kinase. 54 61
19158241 2009
22
Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy. 61 54
19213040 2009
23
Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. 61 54
19129446 2009
24
A 10-year molecular survey of herpes simplex virus type 1 in Germany demonstrates a stable and high prevalence of genotypes A and B. 61 54
19186100 2009
25
The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevention of the nociceptive response by on-site delivery of enkephalins. 54 61
19058913 2009
26
Atopic dermatitis: a disease caused by innate immune defects? 61 54
19078985 2009
27
Delivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways. 61 54
19042034 2009
28
Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1. 54 61
18653740 2008
29
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. 61 54
18728637 2008
30
Herpes simplex virus type 1 Us3 gene deletion influences toll-like receptor responses in cultured monocytic cells. 54 61
19025601 2008
31
Role for nectin-1 in herpes simplex virus 1 entry and spread in human retinal pigment epithelial cells. 61 54
18803666 2008
32
Involvement of HVEM receptor in activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D. 61 54
18671825 2008
33
Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. 61 54
18573279 2008
34
Zhangfei, a novel regulator of the human nerve growth factor receptor, trkA. 54 61
19016376 2008
35
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. 61 54
18667508 2008
36
STAT-1- and IRF-3-dependent pathways are not essential for repression of ICP0-null mutant herpes simplex virus type 1 in human fibroblasts. 54 61
18579584 2008
37
Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. 54 61
18667634 2008
38
HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium. 54 61
18502984 2008
39
Herpes simplex virus type 1 ICP27 regulates expression of a variant, secreted form of glycoprotein C by an intron retention mechanism. 61 54
18495765 2008
40
Effect of conjugation with polypeptide carrier on the enzymatic degradation of Herpes simplex virus glycoprotein D derived epitope peptide. 54 61
18651758 2008
41
[Expression of the radio-inducible TK suicide gene controlled by Egr-1 promoter in pancreatic cancer cells: an in vitro experiment]. 61 54
19062733 2008
42
Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E. 54 61
18480440 2008
43
Uracil-DNA glycosylase (UNG) influences the melting temperature (T(m)) of herpes simplex virus (HSV) hybridization probes. 61 54
18468698 2008
44
High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. 54 61
18287240 2008
45
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. 61 54
18353920 2008
46
[Killing effects of PWZL plasmid-mediated double suicide gene on human lens epithelium cells]. 61 54
18844016 2008
47
Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. 61 54
18160441 2008
48
The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D. 61 54
18076965 2008
49
The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity. 54 61
18949076 2008
50
Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons. 61 54
18066636 2008

Variations for Herpes Simplex

Expression for Herpes Simplex

LifeMap Discovery
Genes differentially expressed in tissues of Herpes Simplex patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCN1 ficolin 1 Skin + 3.89 0.000
2 IRF1 interferon regulatory factor 1 Skin + 3.58 0.000
3 STAT1 signal transducer and activator of transcription 1 Skin + 3.53 0.000
4 PLAAT4 phospholipase A and acyltransferase 4 Skin + 3.49 0.000
5 SERPINB1 serpin family B member 1 Skin + 3.41 0.000
6 CCL19 C-C motif chemokine ligand 19 Skin + 3.32 0.003
7 XAF1 XIAP associated factor 1 Skin + 3.04 0.000
Search GEO for disease gene expression data for Herpes Simplex.

Pathways for Herpes Simplex

Pathways related to Herpes Simplex according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
2
Show member pathways
13.24 TRAF3 TNFRSF14 STAT1 POU2F1 PML IRF3
3
Show member pathways
12.97 TRAF3 TLR3 TICAM1 TBK1 STAT1 IRF3
4
Show member pathways
12.89 TRAF3 TLR3 TICAM1 TBK1 STAT1 IRF3
5
Show member pathways
12.7 TRAF3 TLR3 TICAM1 TBK1 TAP2 TAP1
6
Show member pathways
12.64 TRAF3 TLR3 TICAM1 TBK1 STAT1 IRF3
7
Show member pathways
12.55 TRAF3 TBK1 STAT1 PML EIF2AK2 CREB3
8
Show member pathways
12.47 TLR3 TICAM1 TBK1 IRF3 IFI16
9
Show member pathways
12.45 TRAF3 TNFRSF14 TLR3 CASP8
10 12.42 TRAF3 TLR3 TICAM1 TBK1 TAP2 TAP1
11
Show member pathways
12.41 TRAF3 TBK1 IRF3 CASP8
12
Show member pathways
12.41 TRAF3 TLR3 TICAM1 TBK1 TAP2 TAP1
13
Show member pathways
12.39 STAT1 PML IRF3 EIF2AK2
14
Show member pathways
12.32 TLR3 TICAM1 TBK1 IRF3 CREB3
15 12.25 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1 TAP2
16 12.22 TRAF3 IRF3 EIF2AK2 CREB3 CASP8
17
Show member pathways
12.19 TLR3 TICAM1 STAT1 IRF3
18
Show member pathways
12.17 TRAF3 TLR3 TICAM1 TBK1 IRF3
19 12.12 TRAF3 TICAM1 TBK1 STAT1 IRF3 IFI16
20
Show member pathways
12.09 TLR3 TICAM1 STAT1 EIF2AK2 CASP8
21
Show member pathways
11.89 TLR3 STAT1 CASP8
22 11.83 TRAF3 CREB3 CASP8
23 11.41 STAT1 POU2F1 CASP8
24 11.3 TAP1 STAT1 EIF2AK2
25
Show member pathways
11.07 STAT1 IRF3 EIF2AK2

GO Terms for Herpes Simplex

Cellular components related to Herpes Simplex according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.91 UNC93B1 TLR3 TAP2 TAP1 POU2F1 PML
2 endoplasmic reticulum membrane GO:0005789 9.73 UNC93B1 TLR3 TAP2 TAP1 PML CREB3
3 integral component of endoplasmic reticulum membrane GO:0030176 9.5 TAP2 TAP1 CREB3
4 MHC class I peptide loading complex GO:0042824 9.16 TAP2 TAP1
5 ripoptosome GO:0097342 8.96 TICAM1 CASP8
6 TAP complex GO:0042825 8.62 TAP2 TAP1

Biological processes related to Herpes Simplex according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 TLR3 TBK1 STAT1 POU2F1 IRF3 IFI16
2 apoptotic process GO:0006915 10.08 TRAF3 TICAM1 PML IRF3 IFI16 CASP8
3 innate immune response GO:0045087 10.02 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
4 regulation of apoptotic process GO:0042981 9.93 TRAF3 STAT1 IRF3 CREB3 CASP8
5 immune system process GO:0002376 9.93 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 TLR3 TICAM1 TBK1 IRF3 CASP8
7 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 TRAF3 TNFRSF14 STAT1
8 response to virus GO:0009615 9.84 TLR3 TBK1 EIF2AK2
9 apoptotic signaling pathway GO:0097190 9.82 TLR3 TICAM1 CASP8
10 interferon-gamma-mediated signaling pathway GO:0060333 9.81 STAT1 PML IRF3
11 cellular response to organic cyclic compound GO:0071407 9.81 STAT1 HCFC1 CASP8
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.8 TLR3 TICAM1 TBK1
13 positive regulation of type I interferon production GO:0032481 9.8 TLR3 TICAM1 TBK1 IRF3 IFI16
14 positive regulation of cytokine production GO:0001819 9.79 TLR3 IFI16 EIF2AK2
15 toll-like receptor signaling pathway GO:0002224 9.77 UNC93B1 TRAF3 TLR3
16 extrinsic apoptotic signaling pathway GO:0097191 9.76 TLR3 PML CASP8
17 positive regulation of interferon-beta production GO:0032728 9.76 TLR3 TICAM1 TBK1 IRF3
18 positive regulation of chemokine production GO:0032722 9.75 TLR3 TICAM1 EIF2AK2
19 response to exogenous dsRNA GO:0043330 9.74 TLR3 TICAM1 IRF3
20 positive regulation of interferon-alpha production GO:0032727 9.73 TLR3 TBK1 STAT1 IRF3
21 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.73 TRAF3 TLR3 TICAM1 TBK1 IRF3 CASP8
22 positive regulation of defense response to virus by host GO:0002230 9.72 STAT1 PML CREB3
23 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.67 TLR3 TICAM1
24 cellular response to exogenous dsRNA GO:0071360 9.67 TLR3 IRF3
25 cellular response to interferon-beta GO:0035458 9.67 TLR3 STAT1 IFI16
26 toll-like receptor 3 signaling pathway GO:0034138 9.67 UNC93B1 TLR3 TICAM1 CASP8
27 activation of cysteine-type endopeptidase activity GO:0097202 9.66 IFI16 CASP8
28 regulation of type I interferon production GO:0032479 9.66 TBK1 IRF3
29 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.65 TBK1 IRF3
30 peptide transport GO:0015833 9.65 TAP2 TAP1
31 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.65 TAP2 TAP1
32 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.62 TLR3 TICAM1
33 vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane GO:1990668 9.61 TAP2 TAP1
34 defense response to virus GO:0051607 9.61 UNC93B1 TLR3 TICAM1 TBK1 STAT1 PML
35 virion attachment to host cell GO:0019062 9.6 NECTIN2 NECTIN1
36 release from viral latency GO:0019046 9.56 HCFC1 CREB3
37 cytosol to ER transport GO:0046967 9.52 TAP2 TAP1
38 viral process GO:0016032 9.5 TNFRSF14 TICAM1 TBK1 TAP2 TAP1 STAT1

Molecular functions related to Herpes Simplex according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
2 ubiquitin protein ligase binding GO:0031625 9.83 TRAF3 TNFRSF14 PML CASP8
3 virus receptor activity GO:0001618 9.67 TNFRSF14 NECTIN2 NECTIN1
4 RNA polymerase II core promoter sequence-specific DNA binding GO:0000979 9.54 STAT1 POU2F1
5 MHC protein binding GO:0042287 9.51 TAP2 TAP1
6 protein homodimerization activity GO:0042803 9.5 TAP1 STAT1 PML NECTIN2 NECTIN1 IRF3
7 TAP1 binding GO:0046978 9.48 TAP2 TAP1
8 MHC class Ib protein binding GO:0023029 9.46 TAP2 TAP1
9 identical protein binding GO:0042802 9.44 TRAF3 TLR3 TBK1 STAT1 POU2F1 PML
10 peptide antigen-transporting ATPase activity GO:0015433 9.43 TAP2 TAP1
11 tumor necrosis factor receptor binding GO:0005164 9.43 TRAF3 STAT1 CASP8
12 peptide transmembrane transporter activity GO:1904680 9.4 TAP2 TAP1
13 peptide-transporting ATPase activity GO:0015440 9.37 TAP2 TAP1
14 MHC class I protein binding GO:0042288 9.33 TAP2 TAP1 PILRA

Sources for Herpes Simplex

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....